Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Merck, known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ...

RAHWAY, N.J. - Pharmaceutical giant Merck (NYSE:MRK), with a market capitalization of $203 billion and impressive 77% gross profit margin, will present new data from its HIV research pipeline at ...

Merck’s commitment to HIV For more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment.

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025. Merck (NYSE: MRK), known as MSD outside of the United States and Canada ...

Merck, known as MSD outside of the United States and Canada, announced that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be ...